Dr. Tao, Mi-Hua 's orcid link picture Dr. Tao, Mi-Hua 's publons link picture

Dr. Tao, Mi-Hua

Research Fellow
  • 02-2789-9151 (L) (Lab) (Room No: N229)
  • 02-2652-3078 (O) (Office)
  • 02-2782-9142 (Fax)

Specialty:
  • Viral and Cancer Immunology
  • Viral and Cancer Immunotherapy
  • Vaccine Development
  • Gene Therapy

Education and Positions:
  • Ph.D.  Columbia University (Microbiology and Immunology).

    Postdoctoral Fellow.  Stanford University (Oncology)


  • 日常維護流程─ FACSCelesta
  • 感染性檢體流式細胞儀使用規則(2017)

  • Highlight Detail
    ...

    A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

    Dr. Tao, Mi-Hua
    Emerging Microbes & Infections, Dec 24, 2022

     

     

     

    Numerous vaccines have been developed to address the current COVID-19 pandemic, but safety, cross-neutralizing efficacy, and long-term protectivity of currently approved vaccines are still important issues. In this study, we developed a subunit vaccine, ASD254, by using a nanoparticle vaccine platform to encapsulate the SARS-CoV-2 spike receptor-binding domain (RBD) protein. As compared with the aluminum-adjuvant RBD vaccine, ASD254 induced higher titers of RBD-specific antibodies and generated 10- to 30-fold more neutralizing antibodies. Mice vaccinated with ASD254 showed protective immune responses against SARS-CoV-2 challenge, with undetectable infectious viral loads and reduced typical lesions in lung. Besides, neutralizing antibodies in vaccinated mice lasted for at least one year and were effective against various SARS-CoV-2 variants of concern, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Furthermore, particle size, polydispersity index, and zeta-potential of ASD254 remained stable after 8-month storage at 4°C. Thus, ASD254 is a promising nanoparticle vaccine with good immunogenicity and stability to be developed as an effective vaccine option in controlling upcoming waves of COVID-19.